GlassScriptPhysician profile
Aaron Singh
NPI 1255657060
$2,514.67
in general payments reported to CMS, 2019-2025
20 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $271 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,514.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $408.60 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $299.31 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $242.43 | 2025 | |
| Novo Nordisk INC | $200.52 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $193.12 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Zimmer Biomet Holdings, INC. | $160.92 | 2023 | Persona |
| Viatris Specialty LLC | $140.74 | 2025 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.09 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $139.34 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.56 | 2024-2025 | Xifaxan, Trulance |
| Lundbeck LLC | $116.85 | 2024-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $76.42 | 2025 | Zenpep |
| Dexcom, INC. | $69.00 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $52.39 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $44.39 | 2024-2025 | Repatha, Otezla, Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $28.41 | 2025 | |
| Abbott Laboratories | $21.42 | 2025 | Freestyle Libre 3 |
| Globus Medical, INC. | $19.78 | 2025 | Senza |
| Glaxosmithkline, LLC. | $15.42 | 2025 | Trelegy Ellipta |
| Pfizer INC. | $14.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.